Improvement in quality of life for cancer patients treated with epoetin alfa.

2.50
Hdl Handle:
http://hdl.handle.net/10541/84076
Title:
Improvement in quality of life for cancer patients treated with epoetin alfa.
Authors:
Libretto, S E; Barrett-Lee, P J; Branson, Kate; Gorst, D W; Kaczmarski, R; McAdam, K; Stevenson, P; Thomas, R
Abstract:
Anaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.
Affiliation:
Janssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK. slibrett@jacgb.jnj.com
Citation:
Improvement in quality of life for cancer patients treated with epoetin alfa. 2001, 10 (3):183-91 Eur J Cancer Care
Journal:
European Journal of Cancer Care
Issue Date:
Sep-2001
URI:
http://hdl.handle.net/10541/84076
PubMed ID:
11829381
Type:
Article
Language:
en
ISSN:
0961-5423
Appears in Collections:
All Christie Publications

Full metadata record

DC FieldValue Language
dc.contributor.authorLibretto, S Een
dc.contributor.authorBarrett-Lee, P Jen
dc.contributor.authorBranson, Kateen
dc.contributor.authorGorst, D Wen
dc.contributor.authorKaczmarski, Ren
dc.contributor.authorMcAdam, Ken
dc.contributor.authorStevenson, Pen
dc.contributor.authorThomas, Ren
dc.date.accessioned2009-10-12T15:45:33Z-
dc.date.available2009-10-12T15:45:33Z-
dc.date.issued2001-09-
dc.identifier.citationImprovement in quality of life for cancer patients treated with epoetin alfa. 2001, 10 (3):183-91 Eur J Cancer Careen
dc.identifier.issn0961-5423-
dc.identifier.pmid11829381-
dc.identifier.urihttp://hdl.handle.net/10541/84076-
dc.description.abstractAnaemia is a common complication of cancer and cancer therapies, and fatigue is one of the most common symptoms of anaemia, disrupting functional performance and reducing overall quality of life. The positive effects of treating renal patients with recombinant human erythropoietin are well documented. This case report series details the specific effects of fatigue on individual patients with cancer and their way of life, and describes their significant improvement in lifestyle following the reversal of anaemia using recombinant human erythropoietin, epoetin alfa.en
dc.language.isoenen
dc.subjectHaematinicsen
dc.subjectCanceren
dc.subject.meshAged-
dc.subject.meshAnemia-
dc.subject.meshEpoetin Alfa-
dc.subject.meshFatal Outcome-
dc.subject.meshFemale-
dc.subject.meshHematinics-
dc.subject.meshHumans-
dc.subject.meshMale-
dc.subject.meshMiddle Aged-
dc.subject.meshNeoplasms-
dc.subject.meshQuality of Life-
dc.titleImprovement in quality of life for cancer patients treated with epoetin alfa.en
dc.typeArticleen
dc.contributor.departmentJanssen-Cilag Ltd, High Wycombe, Buckinghamshire, UK. slibrett@jacgb.jnj.comen
dc.identifier.journalEuropean Journal of Cancer Careen
All Items in Christie are protected by copyright, with all rights reserved, unless otherwise indicated.